Randomized placebo- and active-controlled study of desvenlafaxine for menopausal vasomotor symptoms.

@article{Bouchard2012RandomizedPA,
  title={Randomized placebo- and active-controlled study of desvenlafaxine for menopausal vasomotor symptoms.},
  author={Philippe Bouchard and Nick Panay and Tobie J de Villiers and Pascale Vincendon and Wu-an Bao and Ru-fong J Cheng and Gregory Constantine},
  journal={Climacteric : the journal of the International Menopause Society},
  year={2012},
  volume={15 1},
  pages={
          12-20
        }
}
OBJECTIVE To evaluate the efficacy and safety of desvenlafaxine (administered as desvenlafaxine succinate) vs. tibolone and placebo for menopausal vasomotor symptoms and the incidence of uterine bleeding. METHODS This 12-week, double-blind, randomized, controlled trial was conducted at 35 sites in Europe, two sites in South Africa, and one site in Mexico. Postmenopausal women with ≥50 moderate or severe hot flushes per week (n = 485) were randomized to desvenlafaxine 100 mg/day, tibolone 2.5… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-9 OF 9 CITATIONS

Treatment options for vasomotor symptoms in menopause: focus on desvenlafaxine

  • International journal of women's health
  • 2012
VIEW 10 EXCERPTS
CITES BACKGROUND, METHODS & RESULTS
HIGHLY INFLUENCED

Ovarian Ablation in Breast Cancer Patients and the Possibility of Influencing Treatment Side Effects

ablace u pa, cientek s karcinomem, prsu a možnosti, ovlivnění vedlejších, účinků léčby
  • 2016